Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5832.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,4836.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1816.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2353.0,1.0,=,0.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1087.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1083.0,1.0,=,1.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,874.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,727.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,843.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,895.0,1.0,=,0.9
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,650.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,495.0,1.0,=,1.3
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5658.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,3343.0,1.0,=,1.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,4310.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,5180.0,1.0,=,0.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,3383.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1939.0,1.0,=,1.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2292.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2667.0,1.0,=,0.9
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2247.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2165.0,1.0,=,1.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2071.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2014.0,1.0,=,1.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1973.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2766.0,1.0,=,0.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1865.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1998.0,1.0,=,0.9